Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model
- PMID: 15324516
- DOI: 10.1185/030079903125002611
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model
Abstract
Objectives: Various factors influence the risk of complications in type 2 diabetes patients. The isolated impact of single risk factors on long-term outcomes is unclear. The aim of this study was to calculate the projected effects on life expectancy (LE), quality-adjusted LE (QALE) and total costs of complications (TC) of 10% improvements in baseline levels of either total cholesterol (T-CHOL), high-density lipoprotein cholesterol (HDL), systolic blood pressure (SBP), glycosylated haemoglobin (HbA1c), and all four parameters combined.
Methods: A cohort of newly diagnosed patients (baseline age 52 years, HbA1c 9.1%, SBP 137 mmHg, T-CHOL 212 mg/dL, and HDL 39 mg/dL) was defined. The CORE Diabetes Model was used to simulate LE, QALE and TC (US third-party payer perspective discounted at 3% annually) over patients' lifetimes, assuming no change in risk factors, an isolated 10% improvement in each parameter, or a 10% improvement in all parameters simultaneously.
Results: Improved HbA1c led to increases in LE and QALE of 1.00 and 0.81 years respectively, and decreased TC of (US) 10,800 dollars/patient. Improved SBP led to improvements in LE and QALE of 0.67 and 0.55 years respectively and decreased TC of 7,049 dollars. Decreased T-CHOL led to improvements in LE and QALE of 0.29 and 0.20 years, respectively, and increased TC of 1,923 dollars. Increased HDL led to improvements in LE and QALE of 0.28 and 0.18 years respectively, and increased TC of 2,162 dollars. Simultaneous improvements in all parameters led to projected improvements in LE and QALE of 2.17 and 1.72 years respectively, and decreased TC of 14,533 dollars.
Conclusions: Combined improvements in HbA1c, lipid levels and SBP produced the greatest benefits in terms of LE, QALE and TC. A 10% improvement in HbA1c had the greatest impact on these three outcomes.
Similar articles
-
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.Curr Med Res Opin. 2004 Aug;20 Suppl 1:S59-66. doi: 10.1185/030079904X2024. Curr Med Res Opin. 2004. PMID: 15324517
-
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51. doi: 10.1185/030079904X2015. Curr Med Res Opin. 2004. PMID: 15324515
-
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.Curr Med Res Opin. 2004 Aug;20 Suppl 1:S67-73. doi: 10.1185/030079904X2033. Curr Med Res Opin. 2004. PMID: 15324518
-
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.Int J Clin Pract. 2006 Sep;60(9):1138-45. doi: 10.1111/j.1742-1241.2006.01102.x. Int J Clin Pract. 2006. PMID: 16939559 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.Cardiovasc Diabetol. 2009 Feb 26;8:12. doi: 10.1186/1475-2840-8-12. Cardiovasc Diabetol. 2009. PMID: 19245711 Free PMC article. Clinical Trial.
-
Medical assistant health coaching ("MAC") for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol.Contemp Clin Trials. 2021 Jan;100:106164. doi: 10.1016/j.cct.2020.106164. Epub 2020 Oct 11. Contemp Clin Trials. 2021. PMID: 33053431 Free PMC article.
-
Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences.Diabetes Care. 2009 Sep;32(9):1632-8. doi: 10.2337/dc09-0670. Epub 2009 Jun 19. Diabetes Care. 2009. PMID: 19542210 Free PMC article.
-
The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.Diabetes Care. 2006 Feb;29(2):259-64. doi: 10.2337/diacare.29.02.06.dc05-1443. Diabetes Care. 2006. PMID: 16443870 Free PMC article.
-
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.Pharmacoeconomics. 2017 Mar;35(3):319-329. doi: 10.1007/s40273-016-0466-0. Pharmacoeconomics. 2017. PMID: 27873225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical